Rhinosinusitis drug market seen reaching $1.19 billion by 2030

The rhinosinusitis drug market is projected to rise from $0.84 billion in 2026 to $1.19 billion by 2030, driven by more allergic and chronic sinus cases, wider use of existing treatments and growth in digital care tools. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through the forecast period.

Why it matters: - Rhinosinusitis drugs are used to treat inflammation and infection in the nasal passages and sinuses, helping relieve congestion, pressure, pain and mucus buildup. - The market’s growth reflects broader demand for respiratory care as allergy and sinus conditions become more common. - The report points to biologics, targeted immunotherapy and AI-enabled care tools as the next wave of treatment and management.

What happened: - The Business Research Company released its Rhinosinusitis Drug Global Market Report 2026, covering market size, trends and a forecast through 2035. - The rhinosinusitis drug market rose from $0.77 billion in 2025 to $0.84 billion in 2026, a CAGR of 8.9%. - The market is forecast to reach $1.19 billion by 2030, with a CAGR of 9.2%. - The report was published Sept. 14, 2026, from London. - A free sample of the report is available. - The full report is also available.

The details: - Growth in 2025 and 2026 was driven by more allergic and chronic rhinosinusitis cases, heavier use of antibiotics and corticosteroids, more specialized ENT facilities, and wider availability of over-the-counter decongestants and antihistamines. - Rising awareness of respiratory health and earlier diagnosis also supported demand. - The report says future growth will come from biologics, targeted immunotherapy, AI-powered disease management, personalized medicine, non-invasive combination therapies and telemedicine for ENT care. - Expected trends include AI-enhanced diagnostics, wider use of biologics for severe sinus inflammation, combination therapies that address multiple symptoms and remote monitoring through digital platforms. - Rhinosinusitis drugs commonly include anti-inflammatory, antihistamine, decongestant or antimicrobial ingredients. - These treatments are designed to address bacterial, viral or allergic causes of sinus symptoms. - The report says the rise in allergic conditions is a primary market driver. - Allergic disorders can be linked to environmental pollution, lifestyle changes, urbanization and reduced microbial exposure. - The National Asthma Council of Australia reported 474 asthma-related deaths in 2023, including 325 females and 149 males, nearly unchanged from 473 deaths in 2022.

Between the lines: - The market’s near-term growth still depends on familiar therapies, while the longer-term story shifts toward precision treatments and digital care. - Stronger growth in Asia-Pacific suggests demand is broadening beyond mature healthcare markets. - The emphasis on AI and telemedicine signals that diagnosis and follow-up are becoming more important parts of the value chain, not just drug sales.

What's next: - North America is expected to remain a major market because of its established healthcare infrastructure and high awareness. - Asia-Pacific is expected to post the fastest growth as healthcare spending rises and access to new therapies expands. - The report flags South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa as additional regions to watch. - The publisher says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, hotspots infographics and updated trend analysis.

The bottom line: - Rhinosinusitis drug demand is expanding now on common allergy and sinus treatment needs, but the market’s next phase looks tied to biologics, personalized care and digital management tools.